ELI LILLY AND COMPANY |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 816.3 USD | +1.66% |
|
+5.75% | +39.89% |
| 03:59pm | Jefferies Adjusts Price Target on Eli Lilly to $925 From $915 | MT |
| 06:58am | Germany's Gerresheimer to acquire Blitz LuxCo for $866 mln | RE |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
802.9
USD
Average target price
850.4
USD
Spread / Average Target
+5.92%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +40.00% | 723B | |
| +34.28% | 595B | |
| -3.73% | 369B | |
| +20.32% | 332B | |
| +2.83% | 282B | |
| +17.02% | 244B | |
| +9.31% | 208B | |
| -5.07% | 205B | |
| +0.00% | 168B | |
| +7.44% | 166B |
- Stock Market
- Equities
- LLY Stock
- News Eli Lilly and Company
- Cipla Open to Partner With Eli Lilly to Market Obesity Drugs in India
